Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Keryx Biopharmaceuticals commences Phase 2 clinical study evaluating KRX-0401 for Chronic Lymphocytic Leukemia

Keryx Biopharmaceuticals commences Phase 2 clinical study evaluating KRX-0401 for Chronic Lymphocytic Leukemia

pDCs promote growth and survival of malignant myeloma cells

pDCs promote growth and survival of malignant myeloma cells

BioImagene announces launch of the Virtuoso digital pathology solution

BioImagene announces launch of the Virtuoso digital pathology solution

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Leading oncology experts to discuss management of hematological malignancies

Leading oncology experts to discuss management of hematological malignancies

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Multiple Myeloma Research Foundation focuses on effective cancer treatment

Multiple Myeloma Research Foundation focuses on effective cancer treatment

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium's sNDA for VELCADE granted priority review by the FDA

Griffin Securities' report features stem cell hypothesis of cancer

Griffin Securities' report features stem cell hypothesis of cancer

Amgen to present its four Phase 3 clinical trial results

Amgen to present its four Phase 3 clinical trial results

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

Loyola University receives funds to renovate bone marrow transplant unit

Loyola University receives funds to renovate bone marrow transplant unit

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate

Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate

Ascent Therapeutics demonstrates Pepducin efficacy

Ascent Therapeutics demonstrates Pepducin efficacy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.